Two B7-H3 ADCs Post Phase III Overall Survival Wins in Relapsed Small Cell Lung Cancer
Start here
Two B7-H3-targeting antibody-drug conjugates have reported Phase III overall survival successes in relapsed small cell lung cancer, presented at the September 2026 WCLC presidential forum in Seoul. Tambotatug pelitecan (YL-201, MediLink Therapeutics) in the TAISHAN-302 trial and risvutatug rezetecan (HS-20093, from Hansoh partnered with GSK) in ARTEMIS-008 each achieved an overall survival hazard ratio of 0.46. The results challenge a second-line treatment standard that had stood for three decades and place B7-H3 ADCs in direct competition with DLL3 bispecific antibodies in the same setting. Open questions include how the two drug classes will be positioned relative to each other and which patients benefit most from each approach.
Written by a model from the reports · updated 5 days ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickTwo B7-H3 ADCs Post Phase III OS Wins With Hazard Ratio 0.46 in Relapsed Small Cell Lung Cancer
Two B7-H3 antibody-drug conjugates delivered Phase III overall survival wins in relapsed small cell lung cancer at the September 2026 WCLC presidential forum in Seoul. Tambotatug pelitecan (YL-201, from MediLink Therapeutics) in TAISHAN-302 and risvutatug rezetecan (HS-20093, from Hansoh/GSK) in ARTEMIS-008 each hit an overall survival hazard ratio of 0.46, rewriting a second-line standard that had held for three decades and putting B7-H3 ADCs in direct contention with DLL3 bispecifics in the same setting.
Heat trend for this story
Heat now 0·Peak in the comparable set 10 (Oct 19 17:00)·Change over 24h in the comparable set -50%·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.